What did the STEP 9 trial show for semaglutide and knee osteoarthritis?

STEP 9 showed that semaglutide improved knee osteoarthritis symptoms in people with obesity. Participants had a 41.7-point drop in WOMAC pain scores, improved physical function, and mean weight loss of 13.7%, outperforming placebo with lifestyle counseling.

Does semaglutide help knee arthritis only by weight loss, or also by reducing inflammation?

Mostly by weight loss, based on current evidence. Early laboratory, cohort, and conference data suggest GLP-1 therapies may also reduce joint inflammation, but that biology is still emerging and weight loss remains the main proven driver of symptom relief.

Can Semaglutide Help Delay Knee Replacement? What STEP 9 Shows

Q: Can semaglutide help delay knee replacement?

Yes—current evidence suggests semaglutide may help delay knee replacement in some patients with obesity and knee osteoarthritis. STEP 9 showed major improvements in knee pain, physical function, and body weight, and separate orthopedic data link weight loss of 7.5% or more with a 31% lower risk of total knee replacement.

Q: Does weight loss reduce the risk of knee replacement?

Yes. In long-term orthopedic research, losing 7.5% or more of body weight was associated with a 31% lower risk of total knee replacement compared with remaining weight-stable. This was an association, not proof that a specific medication prevents surgery.

Joshua Silva, MD
5 days ago
5 min read

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD

The Short Answer: Current evidence suggests yes. While the STEP 9 Trial specifically validated Semaglutide’s ability to drastically reduce knee pain and improve physical function, separate orthopedic research confirms that losing ≥7.5% of body weight—a milestone routinely surpassed with GLP-1 therapy—is associated with a 31% lower risk of requiring total knee replacement (TKR).

Infographic by Potere Health MD illustrating the mechanical and biological pathways of Semaglutide for knee osteoarthritis relief and surgery prevention.

Does Weight Loss Reduce the Need for Knee Surgery?

Prospective orthopedic data show that losing ≥7.5% of body weight is associated with a 31% lower risk of total knee replacement compared with remaining weight-stable (hazard ratio 0.69).

This was an observational association, not proof that any medication prevents surgery. However, it defines a clinically meaningful weight-loss threshold that GLP-1 and GLP-1/GIP therapies often help patients achieve, potentially delaying progression to knee replacement.

Key takeaway: Losing ≥7.5% of body weight is associated with a 31% lower risk of undergoing total knee replacement in long-term orthopedic studies.

The STEP 9 Trial: Direct Evidence for Pain Relief

The STEP 9 Trial, published in the New England Journal of Medicine, provides the most direct evidence of how Semaglutide transforms life for those with knee osteoarthritis (OA). In this trial, participants achieved:

Massive Pain Reduction: A 41.7-point drop in WOMAC knee pain scores compared to only 27.5 points in placebo group (both with lifestyle counseling.
Clinically Meaningful Mobility: A significant improvement in physical function scores, measured by the SF-36 survey.
Predictable Weight Loss: A mean weight change of -13.7%, nearly double the threshold linked to surgery risk reduction in previous orthopedic studies.

The 4-to-1 Physics of Joint Relief

The relief people feel isn't just biological—it’s mechanical. For every 1 pound of body weight lost, there is a 4-pound reduction in pressure on the knee joint per step. For a St. George or Salt Lake City resident who loses 30 pounds with our program, the cumulative impact is a removal of 120 pounds of force from the knee with every stride. Over a standard Utah hiking day of 5,000 steps, this prevents 600,000 pounds of pressure from grinding against your cartilage.

Do GLP-1/GIP Medications Reduce Joint Inflammation Directly, or Is Relief Just From Weight Loss?

Emerging research suggests YES. GLP-1/GIP medications reduce joint inflammation through a dual-action pathway. While the majority of pain relief comes from reducing mechanical load (weight loss), preliminary data from 2025 indicates that these medications may also have direct anti-inflammatory effects on joint tissue by activating GLP-1 receptors found inside the human knee.

What We Know: The Dual-Pathway of Joint Relief

1. The Mechanical Pathway (Proven)

The most immediate benefit is the reduction of physical "pounding" on the joint. For every 1 pound you lose, you remove 4 pounds of pressure from your knees. Clinical trials like STEP 9 prove that the significant weight loss achieved is the primary driver for massive drops in pain scores and improved function.

2. The Biological Pathway – What the Preliminary Science Suggests

Most of the improvement in knee pain seen with GLP-1 and GLP-1/GIP medications comes from weight loss and reduced mechanical stress on the joint. However, early research suggests these medications may also influence joint inflammation directly, although this area is still evolving.

Here is what the emerging science currently suggests:

Evidence from laboratory and translational studies

GLP-1 receptors have been identified in human knee tissues, including cartilage cells (chondrocytes) and the synovial lining of the joint, supporting the possibility of weight-independent joint effects.
In experimental models, GLP-1 signaling shifts immune cells called macrophages toward a more anti-inflammatory, healing-oriented (M2-like) profile, which could help reduce chronic joint inflammation.

Evidence from observational clinical studies

In the Shanghai Osteoarthritis Cohort, patients treated with GLP-1 receptor agonists showed a slower rate of cartilage loss on MRI compared with similar patients not receiving these therapies.
At ACR Convergence 2025, researchers presented observational and comparative outcomes data suggesting that GLP-1 therapies may be associated with improvements in joint pain and physical function across several rheumatic conditions, including osteoarthritis. These findings reflect symptom improvement, not proof of structural joint repair or receptor-level mechanisms.

A Note on Medical Transparency

Much of this biology-focused research remains preclinical, observational, or reported in conference abstracts and has not yet undergone full peer review. While these findings are promising, they should be viewed as early signals rather than definitive conclusions. At Potere Health MD, we base clinical recommendations primarily on high-quality randomized trials—such as the STEP 9 trial—while closely monitoring developing research.

What Science Still Needs to Confirm

To maintain our standard of medical integrity at Potere Health MD, it's important to be clear about what remains unknown:

How much relief is weight-independent: The exact contribution of biological anti-inflammatory effects versus mechanical weight loss is still uncertain, and most experts believe weight loss remains the dominant factor.
Cartilage Regeneration: There is currently no evidence that GLP-1s can "regrow" lost cartilage; they are best viewed as potentially protective (slowing down damage) rather than restorative.
Long-Term Surgery Prevention: While weight-loss milestones are linked to lower knee replacement risk, data on long-term, medication-specific outcomes are still being collected.

The Bottom Line for Utah Patients

You aren't just getting lighter; you are likely changing the chemical baseline of your joints. By addressing both the weight and the inflammation, GLP-1/GIP therapies offer a comprehensive approach to joint health that goes far beyond traditional "dieting."

Disclaimer:

This article is for educational purposes only and is not a substitute for medical advice.

About the Author

Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. He earned his medical degree from the University of Hawaiʻi John A. Burns School of Medicine and completed residency training in Occupational and Environmental Medicine at the University of Utah, where he also earned a master’s degree in Occupational Health. He later completed a Master of Business Administration with an emphasis in health care administration at Ohio University.

Dr. Silva specializes in evidence-based weight management, including GLP-1 and GIP therapies such as semaglutide and tirzepatide. He provides in-person and virtual care for patients in Salt Lake City, St. George, and Cedar City, Utah.

Sources

Bliddal H, Feldman RG, Gislatun N, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. https://pubmed.ncbi.nlm.nih.gov/39476339/
Jin X, Gibson AA, Gale J, et al. Does weight loss reduce the incidence of total knee and hip replacement for osteoarthritis? A prospective cohort study among middle-aged and older adults with overweight or obesity. Int J Obes (Lond). 2021;45(8):1696-1704. https://pubmed.ncbi.nlm.nih.gov/33993192/
Zhu H, Zhou L, Wang Q, et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis.2023;82(9):1218-1225. https://ard.bmj.com/content/82/9/1218
American College of Rheumatology. New Research at ACR Convergence 2025 Highlights Potential of GLP-1 Therapies in Rheumatic Disease Management. Published October 25, 2025. https://rheumatology.org/press-releases/new-research-at-acr-convergence-2025-highlights-potential-of-glp-1-therapies-in-rheumatic-disease-management
Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263-1273. https://pubmed.ncbi.nlm.nih.gov/24065013/
Meurot C, Jacques C, Martin N, et al. Liraglutide exerts analgesic, anti-inflammatory, and anti-degradative effects in osteoarthritis. Sci Rep. 2022;12:19619. https://pubmed.ncbi.nlm.nih.gov/35091584/
Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M. Glucagon-like peptide-1 induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun. 2012;425(2):304 308. https://pubmed.ncbi.nlm.nih.gov/22842565/